Encompass Health (NYSE:EHC) Rating Lowered to “Hold” at StockNews.com

StockNews.com cut shares of Encompass Health (NYSE:EHC) from a buy rating to a hold rating in a report released on Friday.

A number of other research analysts have also recently weighed in on the stock. Truist Financial restated a “buy” rating and issued a $116.00 price objective (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a research report on Friday. Barclays lifted their target price on Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a report on Friday. Royal Bank of Canada upped their price target on Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Finally, KeyCorp lifted their price objective on Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $107.33.

Encompass Health Stock Up 1.3 %

NYSE:EHC opened at $99.86 on Friday. Encompass Health has a 52 week low of $72.37 and a 52 week high of $104.55. The stock’s fifty day moving average is $96.28 and its two-hundred day moving average is $95.19. The stock has a market capitalization of $10.06 billion, a price-to-earnings ratio of 24.12, a price-to-earnings-growth ratio of 1.18 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88.

Encompass Health (NYSE:EHC) last posted its earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. Research analysts anticipate that Encompass Health will post 4.29 EPS for the current year.

Institutional Investors Weigh In On Encompass Health

Several institutional investors have recently added to or reduced their stakes in EHC. State Street Corp increased its stake in Encompass Health by 0.7% in the third quarter. State Street Corp now owns 3,025,769 shares of the company’s stock valued at $292,410,000 after purchasing an additional 21,329 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Encompass Health by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company’s stock valued at $161,781,000 after buying an additional 20,547 shares during the last quarter. Copeland Capital Management LLC raised its stake in Encompass Health by 0.7% during the 4th quarter. Copeland Capital Management LLC now owns 1,293,098 shares of the company’s stock worth $119,418,000 after acquiring an additional 8,548 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Encompass Health by 2,458.5% in the third quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company’s stock valued at $83,990,000 after acquiring an additional 835,135 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Encompass Health in the fourth quarter valued at $77,944,000. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.